Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Edwin Chiu Yuen Chow"'
Autor:
Anuradha Ramamoorthy, Girish Bende, Edwin Chiu Yuen Chow, Hristina Dimova, Neil Hartman, Daphney Jean, Sonia Pahwa, Yunzhao Ren, Chinmay Shukla, Yuching Yang, Suresh Doddapaneni, Zhixia Yan Danielsen
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 11, Pp 2567-2575 (2022)
Abstract Human radiolabeled mass balance studies are an important component of the clinical pharmacology programs supporting the development of new investigational drugs. These studies allow for understanding of the absorption, distribution, metaboli
Externí odkaz:
https://doaj.org/article/6a45c2e8ac164403ad021fe10f01bcb2
Autor:
Sarah J. Schrieber, Wendy S. Putnam, Edwin Chiu Yuen Chow, Jacek Cieslak, Yanli Zhuang, Steven W. Martin, Paul Hanson, Frank Maggio, Leslie A. Rivera Rosado
Publikováno v:
Drugs in R&D, Vol 20, Iss 4, Pp 301-306 (2020)
Abstract Expedited development programs for biological products to be used in the treatment of serious conditions bring about challenges because of the compressed clinical development timeframes. As expedited development does not lessen the quality e
Externí odkaz:
https://doaj.org/article/a3da12607df14469b1768c5c0151d180
Autor:
Anuradha, Ramamoorthy, Girish, Bende, Edwin Chiu Yuen, Chow, Hristina, Dimova, Neil, Hartman, Daphney, Jean, Sonia, Pahwa, Yunzhao, Ren, Chinmay, Shukla, Yuching, Yang, Suresh, Doddapaneni, Zhixia Yan, Danielsen
Publikováno v:
Clinical and Translational Science. 15:2567-2575
Human radiolabeled mass balance studies are an important component of the clinical pharmacology programs supporting the development of new investigational drugs. These studies allow for understanding of the absorption, distribution, metabolism, and e
Autor:
Sandra J. Casak, Shan Pradhan, Lola A. Fashoyin-Aje, Yi Ren, Yuan-Li Shen, Yuan Xu, Edwin Chiu Yuen Chow, Ye Xiong, Jeanne Fourie Zirklelbach, Jiang Liu, Rosane Charlab, William F. Pierce, Nataliya Fesenko, Julia A. Beaver, Richard Pazdur, Paul G. Kluetz, Steven J. Lemery
Publikováno v:
Clin Cancer Res
On August 25, 2021, the FDA approved ivosidenib for the treatment of adult patients with unresectable locally advanced or metastatic hepatocellular isocitrate dehydrogenase 1 (IDH1) mutated cholangiocarcinoma (CCA) as detected by an FDA-approved test
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af40300243294b5f12940579ab82ce88
https://europepmc.org/articles/PMC9250596/
https://europepmc.org/articles/PMC9250596/
Autor:
Nina Isoherranen, Edwin Chiu Yuen Chow, Benjamin S. Freedman, Suzanne Fitzpatrick, William Hedrich, Ronald L. Wange, Lorna Ewart, William R Proctor, Shannon M. Mumenthaler, Hongbing Wang, Grace L. Guo, Albert P. Li, Stephen S. Ferguson, James J. Hickman, Qi Liu, Paul Brown, Scott Heyward, James E. Polli, Shiew-Mei Huang, Jian Ying Wang, Alexandre J.S. Ribeiro
Publikováno v:
Clinical and Translational Science
Clinical and Translational Science, Vol 14, Iss 5, Pp 1659-1680 (2021)
Clinical and Translational Science, Vol 14, Iss 5, Pp 1659-1680 (2021)
Nonclinical testing has served as a foundation for evaluating potential risks and effectiveness of investigational new drugs in humans. However, the current two‐dimensional (2D) in vitro cell culture systems cannot accurately depict and simulate th
Autor:
Preeti Narayan, William F. Pierce, Richard Pazdur, Edwin Chiu Yuen Chow, Pengfei Song, Harpreet Singh, Laleh Amiri-Kordestani, Kirsten B. Goldberg, Christy L. Osgood, Jingyu Yu, Shenghui Tang, Haw-Jyh Chiu, Julia A. Beaver, Marc R. Theoret, Junshan Qiu, Tiffany K. Ricks, Sherry Hou, Frances Namuswe, Maria Guiterrez-Lugo
Publikováno v:
Clin Cancer Res
On December 20, 2019, the FDA granted accelerated approval to fam-trastuzumab deruxtecan-nxki [DS-8201a; T-DXd; tradename ENHERTU (Daiichi Sankyo)] for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who ha
Autor:
Lynne S. Taylor, Dajun Sun, Niraj S. Trasi, Edwin Chiu Yuen Chow, Hong Wen, Yi Gao, Hitesh S. Purohit, Xinyuan Zhang
Publikováno v:
Journal of pharmaceutical sciences. 107(5)
Delivering a drug in amorphous form in a formulated product is a strategy used to enhance the apparent solubility of a drug substance and its oral bioavailability. Drug crystallization in such products may occur during the manufacturing process or on